Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | UBE2M | P61081 | 7/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 7/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL841826 | 0.99 | PPARG (0.42) | PPARGPPARDPPARALMNAUBE2M | |
| SCHEMBL1981073 | 0.93 | TP53 (0.43) | PPARGPPARDPPARALMNAUBE2M | |
| Hydrochloric Acid SCHEMBL1449403 | 0.92 | MCHR1 (0.45) | PPARGPPARDPPARALMNAUBE2M | |
| Hydrochloric Acid SCHEMBL841986 | 0.92 | TP53 (0.42) | PPARGPPARDPPARALMNAUBE2M | |
| SCHEMBL30227420 | 0.92 | PPARG (0.46) | PPARGPPARDPPARALMNAUBE2M | |
| SCHEMBL1449911 | 0.92 | PPARG (0.46) | PPARGPPARDPPARALMNAUBE2M | |
| Hydrochloric Acid SCHEMBL1448789 | 0.91 | PPARG (0.46) | PPARGPPARDPPARALMNAUBE2M | |
| SCHEMBL1981225 | 0.90 | UBE2M (0.39) | LMNAUBE2MDCUN1D1GALR3RAB9A | |
| Hydrochloric Acid SCHEMBL841487 | 0.89 | UBE2M (0.39) | LMNAUBE2MDCUN1D1GALR3RAB9A | |
| Hydrochloric Acid SCHEMBL1449626 | 0.87 | MCHR1 (0.46) | LMNAUBE2MDCUN1D1MCHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604207-B2 | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-10 | — | — | US | claimed |
| US-20130085275-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-04 | — | — | US | claimed |
| EP-2546234-A1 | Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-01-16 | — | — | EP | claimed |
| US-20110152520-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152520-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | CXCR3, CCR5, CCR1 | PPARG 1090/4885PPARD 1073/4885PPARA 1802/4885 |
| US-20130085275-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | CXCR3, CCR5, CCR1 | PPARG 1090/4885PPARD 1073/4885PPARA 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.